Tris is the Site Leader for a team of 130 scientists responsible for discovering and engineering around half of AstraZeneca’s biologics portfolio. With core technologies such as phage/ribosome display, in vivo platforms, biologics screening and structural biology, his team supports delivery across multiple disease areas of a variety of biologics modalities. Prior to his current appointment, Tris held key responsibilities at Cambridge Antibody Technology and was integral to the successful CAT-AstraZeneca strategic alliance and prior to that for CAT’s Milestone and Royalty based Alliances, including that with Human Genome Sciences that discovered Benylsta®. He also developed the platform technology to build the first human antibody libraries of 1010 members and is a key inventor of Humira®, the world’s best selling medicine. Before joining CAT, he was a postdoctoral fellow at the University of Toronto and a graduate of the University of Leeds Genetics Department. Tristan has over 80 publications in peer-reviewed journals.